TUOXIN

About TUOXIN

Tuoxin Pharmaceutical Group Co., Ltd. is a high-tech enterprise based in Xinxiang, China, that integrates the research, development, production, and sales of nucleoside and nucleotide active pharmaceutical ingredients (APIs) and intermediates. The company was originally founded as Xinxiang Tuoxin Pharmaceutical Co., Ltd. in 2001 by six individuals, including Yang Xining, and was renamed in May 2023. A significant milestone was achieved on October 27, 2021, when the company was successfully listed on the Shenzhen Stock Exchange's ChiNext market.

The company's business model is centered on the production and sale of a wide range of products created through both chemical synthesis and biological fermentation. It has established several technology platforms, including for high-efficiency catalytic synthesis, nucleoside fermentation, and bioconversion semi-synthesis. Tuoxin serves a global client base, distributing its products in both domestic and overseas markets. The product portfolio includes pyrimidine, purine, nucleotide, and nucleoside series, with key products like citicoline sodium, ribavirin, inosine, cytosine, and acyclovir. These ingredients are primarily used in the development of antiviral, anti-tumor, and nervous system medications.

Over the years, Tuoxin has received numerous accolades for its innovation, including having multiple products selected for the "National Torch Program Projects" and receiving a second prize for National Scientific and Technological Progress for its "New process of series nucleoside production." The company operates through several subsidiaries, including Xinxiang Pharmaceutical Co., Ltd., and has been recognized as a "National High-tech Industry Demonstration Project." It holds various certifications, such as ISO9001 and Good Manufacturing Practice (GMP), and has registered products in multiple countries, including India and Japan.